DKDCA vs. BIAF, QH, SUGP, CLIK, KRKR, WWAC, RVYL, LDWY, GRNQ, and SPPL
Should you be buying Data Knights Acquisition stock or one of its competitors? The main competitors of Data Knights Acquisition include bioAffinity Technologies (BIAF), Quhuo (QH), SU Group (SUGP), Click (CLIK), 36Kr (KRKR), Worldwide Webb Acquisition (WWAC), Ryvyl (RVYL), Lendway (LDWY), Greenpro Capital (GRNQ), and Simpple (SPPL). These companies are all part of the "business services" industry.
Data Knights Acquisition vs.
Data Knights Acquisition (NASDAQ:DKDCA) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, community ranking, earnings, dividends and profitability.
Data Knights Acquisition has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -91.22%. Data Knights Acquisition's return on equity of 0.00% beat bioAffinity Technologies' return on equity.
In the previous week, bioAffinity Technologies had 1 more articles in the media than Data Knights Acquisition. MarketBeat recorded 1 mentions for bioAffinity Technologies and 0 mentions for Data Knights Acquisition. bioAffinity Technologies' average media sentiment score of 0.43 beat Data Knights Acquisition's score of 0.00 indicating that bioAffinity Technologies is being referred to more favorably in the news media.
bioAffinity Technologies received 1 more outperform votes than Data Knights Acquisition when rated by MarketBeat users.
35.3% of Data Knights Acquisition shares are held by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are held by institutional investors. 45.7% of Data Knights Acquisition shares are held by insiders. Comparatively, 35.1% of bioAffinity Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Data Knights Acquisition has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Comparatively, bioAffinity Technologies has a beta of 3.45, meaning that its stock price is 245% more volatile than the S&P 500.
bioAffinity Technologies has a consensus price target of $6.00, suggesting a potential upside of 1,237.79%. Given bioAffinity Technologies' stronger consensus rating and higher probable upside, analysts plainly believe bioAffinity Technologies is more favorable than Data Knights Acquisition.
Data Knights Acquisition has higher earnings, but lower revenue than bioAffinity Technologies. Data Knights Acquisition is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.
Summary
bioAffinity Technologies beats Data Knights Acquisition on 8 of the 15 factors compared between the two stocks.
Get Data Knights Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for DKDCA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DKDCA vs. The Competition
Data Knights Acquisition Competitors List
Related Companies and Tools
This page (NASDAQ:DKDCA) was last updated on 5/3/2025 by MarketBeat.com Staff
Buy DKDCA Stock Free DKDCA Stock Alerts